InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,305.84
(
1.13%
)
US TECH 100
18,111.80
(
1.54%
)
Dow Jones
39,893.09
(
0.85%
)
Brent Oil
82.68
(
0.15%
)
Bitcoin
66,248.63
(
7.64%
)
Post# of 251825
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 157016

Saturday, 02/16/2013 10:33:05 AM

Saturday, February 16, 2013 10:33:05 AM

Post# of 251825
Dolutegravir will take share from Isentress in treatment-experienced patients but as you said, its combo with Epzicom isn't an attractive option to Stribild in first line. Still, Isentress annual sales were about $1.5B last year.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up